ProCE Banner Activity

GRAVITAS-119: Phase I Study of Itacitinib Plus Calcineurin Inhibitors as Prophylaxis for GVHD

Slideset Download
Conference Coverage
Early data suggest that the combination of itacitinib and calcineurin inhibitors as prophylaxis for GVHD was well tolerated in patients with hematologic malignancies undergoing stem cell transplantation.

Released: December 18, 2020

Expiration: December 17, 2021

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology